Comparing Orserdu vs Tamoxifen
| Orserdu (elacestrant) | Tamoxifen |
|
|---|
| Orserdu (elacestrant) | Tamoxifen |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Breast Cancer. Orserdu may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer - Adjuvant, Breast Cancer - Metastatic, Breast Cancer, Breast Cancer - Male, Breast Cancer - Palliative, Breast Cancer - Prevention, McCune-Albright Syndrome, Precocious... View more |
Related suggestions Breast Cancer
|
|||||||||||||||
| More about Orserdu (elacestrant) | More about Tamoxifen | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Be the first to share your experience with this drug. |
Tamoxifen has an average rating of 5.6 out of 10 from a total of 97 ratings on Drugs.com. 32% of reviewers reported a positive effect, while 29% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Orserdu side effects |
View all Tamoxifen side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
Lower cost generic |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Orserdu prices |
View all Tamoxifen prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
|
N/A |
Soltamox | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
50 hours |
231 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 291 drugs are known to interact with Orserdu:
|
A total of 459 drugs are known to interact with Tamoxifen:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
January 27, 2023 |
December 30, 1977 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
|||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
Herceptin
Herceptin is used to treat patients with metastatic breast cancer. Learn about side effects ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.